Investigators presented final six-month data from the EPILOG trial of Centocor Inc.'s ReoPro GPIIb/IIIa inhibitor in all comers undergoing angioplasty. As reported Sunday at the American Heart Association meeting in
Read the full 302 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury